Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach.
COVID-19
SARS-CoV-2
allergic reactions
anaphylaxis
mRNA COVID-19 vaccine
polyethylene glycol
polysorbate 80
repeat allergic reactions
skin testing
vaccination
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
12
04
2023
revised:
08
05
2023
accepted:
11
05
2023
medline:
7
8
2023
pubmed:
10
6
2023
entrez:
9
6
2023
Statut:
ppublish
Résumé
This guidance updates 2021 GRADE (Grading of Recommendations Assessment, Development and Evaluation) recommendations regarding immediate allergic reactions following coronavirus disease 2019 (COVID-19) vaccines and addresses revaccinating individuals with first-dose allergic reactions and allergy testing to determine revaccination outcomes. Recent meta-analyses assessed the incidence of severe allergic reactions to initial COVID-19 vaccination, risk of mRNA-COVID-19 revaccination after an initial reaction, and diagnostic accuracy of COVID-19 vaccine and vaccine excipient testing in predicting reactions. GRADE methods informed rating the certainty of evidence and strength of recommendations. A modified Delphi panel consisting of experts in allergy, anaphylaxis, vaccinology, infectious diseases, emergency medicine, and primary care from Australia, Canada, Europe, Japan, South Africa, the United Kingdom, and the United States formed the recommendations. We recommend vaccination for persons without COVID-19 vaccine excipient allergy and revaccination after a prior immediate allergic reaction. We suggest against >15-minute postvaccination observation. We recommend against mRNA vaccine or excipient skin testing to predict outcomes. We suggest revaccination of persons with an immediate allergic reaction to the mRNA vaccine or excipients be performed by a person with vaccine allergy expertise in a properly equipped setting. We suggest against premedication, split-dosing, or special precautions because of a comorbid allergic history.
Identifiants
pubmed: 37295474
pii: S0091-6749(23)00746-7
doi: 10.1016/j.jaci.2023.05.019
pmc: PMC10247143
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccine Excipients
0
Excipients
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
309-325Subventions
Organisme : AHRQ HHS
ID : K12 HS026395
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI109565
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001426
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001425
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150295
Pays : United States
Informations de copyright
Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.